0.3551
5.05%
-0.0189
Cyclacel Pharmaceuticals Inc stock is traded at $0.3551, with a volume of 229.47K.
It is down -5.05% in the last 24 hours and down -68.85% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
See More
Previous Close:
$0.374
Open:
$0.365
24h Volume:
229.47K
Relative Volume:
0.17
Market Cap:
$797.85K
Revenue:
-
Net Income/Loss:
$-22.56M
P/E Ratio:
-0.184
EPS:
-1.93
Net Cash Flow:
$-16.12M
1W Performance:
-20.91%
1M Performance:
-68.85%
6M Performance:
-84.49%
1Y Performance:
+17.50%
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
CYCC | 0.3551 | 797.85K | 0 | -22.56M | -16.12M | -1.93 |
VRTX | 467.02 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 759.96 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.96 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 231.19 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.53 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-18-22 | Resumed | Oppenheimer | Outperform |
Apr-27-20 | Resumed | ROTH Capital | Buy |
Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
Oct-16-15 | Initiated | H.C. Wainwright | Buy |
Feb-04-10 | Initiated | Roth Capital | Buy |
Oct-28-09 | Initiated | Merriman | Buy |
Aug-12-08 | Initiated | Piper Jaffray | Buy |
Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
Mar-12-08 | Reiterated | Collins Stewart | Buy |
Mar-12-08 | Reiterated | Needham & Co | Buy |
Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
Jun-04-07 | Reiterated | Needham & Co | Buy |
Apr-23-07 | Initiated | Lazard Capital | Buy |
Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Armistice Capital, LLC Increases Stake in Cyclacel Pharmaceutica - GuruFocus.com
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss - MSN
Cyclacel stock plunges to 52-week low of $0.37 amid market challenges - Investing.com Canada
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise Deal at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals appoints new auditor By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals appoints new auditor - Investing.com India
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Faces Delisting Risk Despite 67% Lower Q3 Loss; Cash Concerns Mount | CYCC Stock News - StockTitan
(CYCCP) Technical Pivots with Risk Controls - Stock Traders Daily
A Data-Based Look At Cyclacel Pharmaceuticals Inc (CYCC) - Stocks Register
Cyclacel stock plunges to 52-week low at $0.6 amid market challenges - Investing.com
Cyclacel stock plunges to 52-week low at $0.74 amid market challenges - Investing.com India
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - The Manila Times
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - ForexTV.com
Nasopharyngeal Cancer Market Report: Growth Forecast and Key - openPR
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
CYCCPCyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94 - MSN
Cyclacel stock plunges to 52-week low, touches $0.8 By Investing.com - Investing.com Australia
Cyclacel stock plunges to 52-week low, touches $0.8 - Investing.com
CYCCCyclacel Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - The Manila Times
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - ForexTV.com
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
(CYCCP) Trading Report - Stock Traders Daily
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Cyclacel halts dividend on preferred stock - Investing.com
Cyclacel halts dividend on preferred stock By Investing.com - Investing.com Canada
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - ForexTV.com
Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Benzinga
Cyclacel Pharmaceuticals Inc (CYCC)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Metric Analysis: Cyclacel Pharmaceuticals Inc (CYCC)’s Key Ratios in the Limelight - The Dwinnex
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cyclacel Pharmaceuticals Inc Stock (CYCC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Rombotis Spiro George | President and CEO |
Dec 21 '23 |
Buy |
3.31 |
6,070 |
20,122 |
68,658 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):